JP2012533570A5 - - Google Patents

Download PDF

Info

Publication number
JP2012533570A5
JP2012533570A5 JP2012520827A JP2012520827A JP2012533570A5 JP 2012533570 A5 JP2012533570 A5 JP 2012533570A5 JP 2012520827 A JP2012520827 A JP 2012520827A JP 2012520827 A JP2012520827 A JP 2012520827A JP 2012533570 A5 JP2012533570 A5 JP 2012533570A5
Authority
JP
Japan
Prior art keywords
oxy
ppm
methyloxy
cyclopropane
morpholin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012520827A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012533570A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/042353 external-priority patent/WO2011009095A1/en
Publication of JP2012533570A publication Critical patent/JP2012533570A/ja
Publication of JP2012533570A5 publication Critical patent/JP2012533570A5/ja
Pending legal-status Critical Current

Links

JP2012520827A 2009-07-17 2010-07-16 N−[3−フルオロ−4−({6−(メチルオキシ)−7−[(3−モルホリン−4−イルプロピル)オキシ]−キノリン−4−イル}オキシ)フェニル]−n’−(4−フルオロフェニル)シクロプロパン−1,1−ジカルボキサミドの結晶形 Pending JP2012533570A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22650909P 2009-07-17 2009-07-17
US61/226,509 2009-07-17
PCT/US2010/042353 WO2011009095A1 (en) 2009-07-17 2010-07-16 Crystalline forms of n-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]-quin0lin-4-yl}oxy)phenyl]-n'-(4-fluorophenyl)cyclopropane-1, 1-dicarboxamide

Publications (2)

Publication Number Publication Date
JP2012533570A JP2012533570A (ja) 2012-12-27
JP2012533570A5 true JP2012533570A5 (OSRAM) 2013-08-29

Family

ID=42712017

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012520827A Pending JP2012533570A (ja) 2009-07-17 2010-07-16 N−[3−フルオロ−4−({6−(メチルオキシ)−7−[(3−モルホリン−4−イルプロピル)オキシ]−キノリン−4−イル}オキシ)フェニル]−n’−(4−フルオロフェニル)シクロプロパン−1,1−ジカルボキサミドの結晶形

Country Status (15)

Country Link
US (1) US8673912B2 (OSRAM)
EP (1) EP2454238A1 (OSRAM)
JP (1) JP2012533570A (OSRAM)
KR (1) KR20120051702A (OSRAM)
CN (1) CN102510855B (OSRAM)
AU (1) AU2010274012A1 (OSRAM)
BR (1) BR112012001118A2 (OSRAM)
CA (1) CA2768370A1 (OSRAM)
EA (1) EA201200144A1 (OSRAM)
IL (1) IL217537A0 (OSRAM)
MX (1) MX2012000809A (OSRAM)
NZ (1) NZ597695A (OSRAM)
TW (1) TW201118072A (OSRAM)
WO (1) WO2011009095A1 (OSRAM)
ZA (1) ZA201200389B (OSRAM)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005030140A2 (en) 2003-09-26 2005-04-07 Exelixis, Inc. C-met modulators and methods of use
DK2387563T4 (da) 2009-01-16 2022-07-18 Exelixis Inc Malatsalt af n-(4-{ [ 6, 7-bis(methyloxy)quinolin-4-yl]oxy}phenyl-n'-(4-fluorphenyl)cyclopropan-1,1-dicarboxamid, og krystallinske former deraf til behandling af cancer
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
MX2012010506A (es) * 2010-03-12 2012-10-15 Exelixis Inc Formas cristalinas hidratadas del n-[3-fluoro-4-({6-(metiloxi)-7-[ (3-morfolin-4-ilpropil)oxi]-quinolin-4-il}oxi)fenil]-n'-(4-fluoro fenil)ciclopropano-1,1-dicarboxamida.
SG187060A1 (en) 2010-07-16 2013-02-28 Exelixis Inc C-met modulator pharmaceutical compositions
US20140057943A1 (en) 2010-09-27 2014-02-27 Exelixix, Inc. Method of Treating Cancer
KR20230158644A (ko) 2011-02-10 2023-11-20 엑셀리시스, 인코포레이티드 퀴놀린 화합물들의 제조 방법들 및 상기 화합물들을 함유하는 약학 조성물들
US20120252840A1 (en) 2011-04-04 2012-10-04 Exelixis, Inc. Method of Treating Cancer
WO2012151326A1 (en) 2011-05-02 2012-11-08 Exelixis, Inc. Method of treating cancer and bone cancer pain
CA2848512A1 (en) 2011-09-22 2013-03-28 Exelixis, Inc. Method for treating osteoporosis
BR112014009302B1 (pt) 2011-10-20 2020-04-28 Exelis Inc Us/Us processo para preparar derivados de quinolina
US9861624B2 (en) 2012-05-02 2018-01-09 Exelixis, Inc. Method of treating cancer
GEP20196995B (en) 2013-03-15 2019-07-25 Inc Exelixis Metabolites of n-(4-{[6,7-bis (methyloxy)quinolin-4-yl] oxy}phenyl)-n'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide
ES2927651T3 (es) 2013-04-04 2022-11-10 Exelixis Inc Forma de dosificación de cabozantinib y uso en el tratamiento del cáncer
AU2014248001A1 (en) * 2013-04-04 2015-11-19 Exelixis, Inc. Drug combinations to treat cancer
EP3738952A1 (en) 2014-02-14 2020-11-18 Exelixis, Inc. Crystalline solid forms of n-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-n'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use
JP6666849B2 (ja) 2014-03-17 2020-03-18 エグゼリクシス, インコーポレイテッド カボザンチニブ製剤の投与
EP3174854B1 (en) 2014-07-31 2022-08-24 Exelixis, Inc. Method of preparing fluorine-18 labeled cabozantinib and its analogs
CN106573042A (zh) 2014-08-05 2017-04-19 埃克塞里艾克西斯公司 治疗多发性骨髓瘤的药物组合
CN109069499A (zh) 2016-04-15 2018-12-21 埃克塞里艾克西斯公司 使用 n-(4-(6,7-二甲氧基喹啉-4-基氧基)苯基)-n’-(4-氟苯基)环丙烷-1,1-二甲酰胺,(2s)-羟基丁二酸盐治疗肾细胞癌的方法
WO2017199903A1 (ja) 2016-05-16 2017-11-23 帝人ファーマ株式会社 キノリン誘導体の結晶
EP3806858A4 (en) 2018-06-15 2022-03-09 Handa Pharmaceuticals, Inc. KINA INHIBITOR SALTS AND COMPOSITIONS THEREOF
US12227536B2 (en) 2018-12-20 2025-02-18 Merck Sharp & Dohme Llc Crystalline forms of an NRTTI compound
CN110357814A (zh) * 2019-07-12 2019-10-22 上海翔锦生物科技有限公司 对甲苯磺酸盐新晶型及其应用
EP4658271A1 (en) 2023-01-31 2025-12-10 Handa Oncology, LLC Improved cabozantinib compositions and methods of use

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100883731B1 (ko) 2001-06-22 2009-02-12 기린 파마 가부시끼가이샤 간세포 증식 인자 수용체 자기 인산화를 저해하는 퀴놀린유도체 및 퀴나졸린 유도체 및 이들을 함유하는 의약 조성물
US20050043233A1 (en) * 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
WO2005030140A2 (en) * 2003-09-26 2005-04-07 Exelixis, Inc. C-met modulators and methods of use
WO2010056960A1 (en) 2008-11-13 2010-05-20 Exelixis Inc. Methods of preparing quinoline derivatives

Similar Documents

Publication Publication Date Title
JP2012533570A5 (OSRAM)
JP2013522232A5 (OSRAM)
CN115244058A (zh) 嘧啶并二环类衍生物、其制备方法及其在医药上的应用
RU2490258C2 (ru) ПРОИЗВОДНЫЕ ГИДРОБЕНЗАМИДА В КАЧЕСТВЕ ИНГИБИТОРОВ Hsp90
CA2606719A1 (en) Amorphous salt of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide and process for producing the same
JP2013535491A5 (OSRAM)
JP2020521732A5 (OSRAM)
RU2020111019A (ru) Полиморфная форма tg02
JP2015509537A5 (OSRAM)
CA2543650A1 (en) A crystalline form of the salt of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide or the solvate of the salt and a process for preparing the same
JP2018531280A5 (OSRAM)
JP2011509309A5 (OSRAM)
JP2012532112A5 (OSRAM)
JP2008525530A5 (OSRAM)
JP2015512942A5 (OSRAM)
JP2014520898A5 (OSRAM)
JP2010501519A5 (OSRAM)
JP2010540509A5 (OSRAM)
JP2018516883A5 (OSRAM)
KR20170048543A (ko) 진정제 및 마취제의 제조에서의 gabaa 수용체 강화제의 용도
JP2012180344A5 (OSRAM)
JP2011509301A5 (OSRAM)
RU2016122731A (ru) Функционализированные и замещенные индолы в качестве противораковых агентов
JP2015522551A5 (OSRAM)
JP2012509279A5 (OSRAM)